Quoin Pharmaceuticals Files for Breakthrough Designation for QRX003, Potential First Treatment for Netherton Syndrome
- Breakthrough Application: Quoin Pharmaceuticals has filed for Breakthrough Medicine Designation for QRX003 with the Saudi Food and Drug Authority, which, if granted, will expedite the review process and potentially allow early patient access by the second half of 2026, marking a historic milestone in the treatment of Netherton Syndrome.
- Clinical Trial Progress: QRX003 is currently undergoing two pivotal whole-body clinical trials, with enrollment expected to complete in the first half of 2026 and top-line data anticipated in the second half, providing critical evidence for subsequent drug applications and facilitating market entry.
- Significant Market Potential: If approved, QRX003 will be the first-ever treatment for Netherton Syndrome globally, and Quoin's distribution partnership with Genpharm will ensure its promotion in Saudi Arabia and other MENA countries, addressing the urgent need for rare disease therapies in the region.
- Regulatory Support Strengthened: QRX003 has received Orphan Drug and Pediatric Rare Disease Designations from the U.S. FDA and Orphan Drug Designation from the European Medicines Agency, indicating strong regulatory recognition worldwide and enhancing Quoin's competitive position in the rare disease market.
Trade with 70% Backtested Accuracy
Analyst Views on QNRX
No data
About QNRX
About the author
Quoin Pharmaceuticals Files for Breakthrough Designation for QRX003, Potential First Treatment for Netherton Syndrome
- Breakthrough Application: Quoin Pharmaceuticals has filed for Breakthrough Medicine Designation for QRX003 with the Saudi Food and Drug Authority, which, if granted, will expedite the review process and potentially allow early patient access by the second half of 2026, marking a historic milestone in the treatment of Netherton Syndrome.
- Clinical Trial Progress: QRX003 is currently undergoing two pivotal whole-body clinical trials, with enrollment expected to complete in the first half of 2026 and top-line data anticipated in the second half, providing critical evidence for subsequent drug applications and facilitating market entry.
- Significant Market Potential: If approved, QRX003 will be the first-ever treatment for Netherton Syndrome globally, and Quoin's distribution partnership with Genpharm will ensure its promotion in Saudi Arabia and other MENA countries, addressing the urgent need for rare disease therapies in the region.
- Regulatory Support Strengthened: QRX003 has received Orphan Drug and Pediatric Rare Disease Designations from the U.S. FDA and Orphan Drug Designation from the European Medicines Agency, indicating strong regulatory recognition worldwide and enhancing Quoin's competitive position in the rare disease market.
Quoin Pharmaceuticals Stock Rises 21% Following Topical Rapamycin Achievement
Stock Performance: Quoin Pharmaceuticals Ltd. (QNRX) saw a 21.15% increase in stock price, reaching $9.99, following the announcement of successful rapamycin loadings in their topical delivery platforms.
Clinical Development Plans: The company intends to manufacture clinical trial and stability batches in Q4 2025 and start clinical testing in the first half of 2026 for conditions like microcystic lymphatic malformations and venous malformations, which currently have no FDA-approved treatments.
Trading Activity: The announcement led to unusually high trading volume for QNRX, indicating strong investor interest in the company's developments.
Stock Range: The stock's 52-week price range is noted to be between $2.65 and $9.99.
US Stocks Show Varied Performance; Sea Shares Rise Following Q3 Earnings Report
Market Performance: U.S. stocks showed mixed results, with the Dow up 0.13% while the Nasdaq fell 0.42% and the S&P 500 dropped 0.15%. Energy shares increased by 0.9%, but information technology stocks declined by 0.7%.
Company Highlights: Sea Ltd's shares rose 4% after reporting a 38.3% increase in quarterly revenue, despite missing earnings expectations. MSP Recovery Inc saw a significant 104% increase in its stock price.
Declining Stocks: Vor Biopharma Inc and Salarius Pharmaceuticals Inc experienced substantial drops of 48% and 50%, respectively, following announcements related to public offerings. Outset Medical Inc also fell 42% after disappointing financial results.
Global Market Trends: European shares rose, with the eurozone's STOXX 600 up 0.8%, while Asian markets closed mixed, with Japan's Nikkei 225 down slightly and India's BSE Sensex up 0.40%.
Quoin Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for QRX003 in Netherton Syndrome
FDA Approval and Orphan Drug Designation: Quoin Pharmaceuticals has received Orphan Drug Designation from the FDA for its product QRX003, aimed at treating Netherton Syndrome, following a similar designation from the EMA in May 2025.
Market Exclusivity and Benefits: If approved, QRX003 will enjoy seven years of marketing exclusivity in the U.S., along with benefits such as tax credits for clinical testing and reduced FDA application fees.
Clinical Trials and Development Timeline: QRX003 is currently being evaluated in two late-stage pivotal clinical trials, with enrollment expected to complete by Q1 2026 and top-line data anticipated in the second half of 2026.
Company Commitment: Quoin Pharmaceuticals emphasizes its dedication to advancing QRX003's clinical development to address the unmet medical needs of patients suffering from Netherton Syndrome and other rare diseases.
What’s Driving Quoin Pharmaceuticals' Pre-market Surge?
FDA Orphan Drug Designation: Quoin Pharmaceuticals has received Orphan Drug Designation from the FDA for its product candidate QRX003, aimed at treating Netherton Syndrome, following a similar designation from the European Medicines Agency in May 2025.
Clinical Trials and Timeline: QRX003 lotion is currently undergoing two late-stage pivotal clinical trials, with enrollment expected to finish by Q1 2026, top-line data anticipated in the second half of 2026, and a New Drug Application (NDA) submission planned for later that year.
Market Reaction: Following the announcement, Quoin Pharmaceuticals' shares rose by 8% in pre-market trading on Tuesday.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Reasons Behind the Surge in Quoin Pharmaceuticals Stock (QNRX) Today
Stock Surge: Quoin Pharmaceuticals (QNRX) stock rose by approximately 157% following the announcement of a $104.5 million funding deal, indicating strong investor interest and confidence in the company's pipeline.
Funding Details: The deal includes an initial cash infusion of $16.5 million and potential additional funding through warrant exercises, aimed at supporting operations and the clinical development of its lead candidate, QRX003, into 2027.
Quoin Pharmaceuticals Files for Breakthrough Designation for QRX003, Potential First Treatment for Netherton Syndrome
- Breakthrough Application: Quoin Pharmaceuticals has filed for Breakthrough Medicine Designation for QRX003 with the Saudi Food and Drug Authority, which, if granted, will expedite the review process and potentially allow early patient access by the second half of 2026, marking a historic milestone in the treatment of Netherton Syndrome.
- Clinical Trial Progress: QRX003 is currently undergoing two pivotal whole-body clinical trials, with enrollment expected to complete in the first half of 2026 and top-line data anticipated in the second half, providing critical evidence for subsequent drug applications and facilitating market entry.
- Significant Market Potential: If approved, QRX003 will be the first-ever treatment for Netherton Syndrome globally, and Quoin's distribution partnership with Genpharm will ensure its promotion in Saudi Arabia and other MENA countries, addressing the urgent need for rare disease therapies in the region.
- Regulatory Support Strengthened: QRX003 has received Orphan Drug and Pediatric Rare Disease Designations from the U.S. FDA and Orphan Drug Designation from the European Medicines Agency, indicating strong regulatory recognition worldwide and enhancing Quoin's competitive position in the rare disease market.
Quoin Pharmaceuticals Stock Rises 21% Following Topical Rapamycin Achievement
Stock Performance: Quoin Pharmaceuticals Ltd. (QNRX) saw a 21.15% increase in stock price, reaching $9.99, following the announcement of successful rapamycin loadings in their topical delivery platforms.
Clinical Development Plans: The company intends to manufacture clinical trial and stability batches in Q4 2025 and start clinical testing in the first half of 2026 for conditions like microcystic lymphatic malformations and venous malformations, which currently have no FDA-approved treatments.
Trading Activity: The announcement led to unusually high trading volume for QNRX, indicating strong investor interest in the company's developments.
Stock Range: The stock's 52-week price range is noted to be between $2.65 and $9.99.
US Stocks Show Varied Performance; Sea Shares Rise Following Q3 Earnings Report
Market Performance: U.S. stocks showed mixed results, with the Dow up 0.13% while the Nasdaq fell 0.42% and the S&P 500 dropped 0.15%. Energy shares increased by 0.9%, but information technology stocks declined by 0.7%.
Company Highlights: Sea Ltd's shares rose 4% after reporting a 38.3% increase in quarterly revenue, despite missing earnings expectations. MSP Recovery Inc saw a significant 104% increase in its stock price.
Declining Stocks: Vor Biopharma Inc and Salarius Pharmaceuticals Inc experienced substantial drops of 48% and 50%, respectively, following announcements related to public offerings. Outset Medical Inc also fell 42% after disappointing financial results.
Global Market Trends: European shares rose, with the eurozone's STOXX 600 up 0.8%, while Asian markets closed mixed, with Japan's Nikkei 225 down slightly and India's BSE Sensex up 0.40%.
Quoin Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for QRX003 in Netherton Syndrome
FDA Approval and Orphan Drug Designation: Quoin Pharmaceuticals has received Orphan Drug Designation from the FDA for its product QRX003, aimed at treating Netherton Syndrome, following a similar designation from the EMA in May 2025.
Market Exclusivity and Benefits: If approved, QRX003 will enjoy seven years of marketing exclusivity in the U.S., along with benefits such as tax credits for clinical testing and reduced FDA application fees.
Clinical Trials and Development Timeline: QRX003 is currently being evaluated in two late-stage pivotal clinical trials, with enrollment expected to complete by Q1 2026 and top-line data anticipated in the second half of 2026.
Company Commitment: Quoin Pharmaceuticals emphasizes its dedication to advancing QRX003's clinical development to address the unmet medical needs of patients suffering from Netherton Syndrome and other rare diseases.
What’s Driving Quoin Pharmaceuticals' Pre-market Surge?
FDA Orphan Drug Designation: Quoin Pharmaceuticals has received Orphan Drug Designation from the FDA for its product candidate QRX003, aimed at treating Netherton Syndrome, following a similar designation from the European Medicines Agency in May 2025.
Clinical Trials and Timeline: QRX003 lotion is currently undergoing two late-stage pivotal clinical trials, with enrollment expected to finish by Q1 2026, top-line data anticipated in the second half of 2026, and a New Drug Application (NDA) submission planned for later that year.
Market Reaction: Following the announcement, Quoin Pharmaceuticals' shares rose by 8% in pre-market trading on Tuesday.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Reasons Behind the Surge in Quoin Pharmaceuticals Stock (QNRX) Today
Stock Surge: Quoin Pharmaceuticals (QNRX) stock rose by approximately 157% following the announcement of a $104.5 million funding deal, indicating strong investor interest and confidence in the company's pipeline.
Funding Details: The deal includes an initial cash infusion of $16.5 million and potential additional funding through warrant exercises, aimed at supporting operations and the clinical development of its lead candidate, QRX003, into 2027.
